HC Wainwright Reiterates “Buy” Rating for MediWound (NASDAQ:MDWD)

MediWound (NASDAQ:MDWD – Get Rating)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They presently have a $23.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 110.43% from the company’s previous close.

MDWD has been the subject of several other research reports. StockNews.com initiated coverage on MediWound in a research note on Thursday. They issued a “hold” rating for the company. Cowen raised their price target on MediWound from $6.00 to $25.00 and gave the company an “outperform” rating in a report on Friday, December 30th. Finally, Maxim Group assumed coverage on MediWound in a report on Thursday, December 22nd. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, MediWound presently has an average rating of “Moderate Buy” and an average target price of $40.40.

MediWound Stock Up 2.6 %

Shares of NASDAQ MDWD opened at $10.93 on Friday. MediWound has a 52 week low of $8.05 and a 52 week high of $17.08. The business has a 50-day simple moving average of $12.69 and a two-hundred day simple moving average of $11.47. The company has a market cap of $63.61 million, a P/E ratio of -2.95 and a beta of 0.98.

Hedge Funds Weigh In On MediWound

Large investors have recently modified their holdings of the company. Renaissance Technologies LLC raised its holdings in shares of MediWound by 3.8% during the 2nd quarter. Renaissance Technologies LLC now owns 475,422 shares of the biopharmaceutical company’s stock valued at $875,000 after buying an additional 17,600 shares in the last quarter. PNC Financial Services Group Inc. purchased a new position in shares of MediWound during the 4th quarter valued at about $57,000. Essex Investment Management Co. LLC purchased a new position in shares of MediWound during the 3rd quarter valued at about $405,000. Armistice Capital LLC purchased a new position in shares of MediWound during the 3rd quarter valued at about $2,663,000. Finally, Altium Capital Management LP purchased a new position in shares of MediWound during the 3rd quarter valued at about $1,775,000. 13.58% of the stock is owned by hedge funds and other institutional investors.

About MediWound

(Get Rating)

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.